Oncol Case Rep J | Volume 8, Issue 1 | Case Report | Open Access

First Reported Case of Upper Gastrointestinal Bleeding due to Dieulafoy Lesion in a Patient Undergoing Cabozantinib Treatment for Renal Cell Carcinoma: A Case Report

Murat Basaran^1*, Mehmet Kapan², Etibar Mammadov², Nejla Kucuk², Hasan Tunca³, Mehmet Suat Yalcın¹ and Burak Ozseker²

¹Mugla Education and Research Hospital Gastroenterology, Turkey  ²Department of Gastroenterology, Mugla Sıtkı Kocman University Medicine  ³Department of İnternal Medicine, Mugla Sıtkı Kocman University Medicine, Turkey

^*Correspondance to: Murat Basaran 

Abstract

Cabozantinib, a multi-kinase inhibitor widely used in the treatment of renal cell carcinoma (RCC), is associated with a spectrum of adverse effects, among which gastrointestinal (GI) toxicity remains noteworthy. However, the occurrence of upper gastrointestinal bleeding (UGIB) induced by cabozantinib is sparsely documented. Herein, we discuss the case of a 62-year-old male patient with RCC on cabozantinib therapy who developed melena secondary to a Dieulafoy lesion. Although he was hemodynamically stable at presentation, laboratory assessments revealed substantial blood loss. Esophagogastroduodenoscopy (EGD) identified the Dieulafoy lesion as the bleeding source, and hemostasis was achieved using adrenaline injections paired with hemoclips placement. This case underscores the potential association between cabozantinib therapy and UGIB, highlighting the necessity for vigilant monitoring in this patient population.

Keywords:

#

Citation:

Basaran M, Kapan M, Mammadov E, Kucuk N, Tunca H, Suat Yalcın M, et al. First Reported Case of Upper Gastrointestinal Bleeding due to Dieulafoy Lesion in a Patient Undergoing Cabozantinib Treatment for Renal Cell Carcinoma: A Case Report. Oncol Case Report J. 2025; 8(1): 1066..